ロード中...
Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients
Approximately 2 million Japanese individuals are infected with hepatitis C virus and are at risk for cirrhosis, end‐stage liver disease, and hepatocellular carcinoma. Patients in whom interferon (IFN)/ribavirin (RBV) therapy has failed remain at risk as effective therapeutic options are limited. Thi...
保存先:
| 出版年: | Hepatology |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2015
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5763364/ https://ncbi.nlm.nih.gov/pubmed/25644279 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.27705 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|